Is Now a Good Time to Buy Moderna Stock?

54
15
Favorite

Is Now a Good Time to Buy Moderna Stock?

Motley Fool2022-01-05

While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（15）

lawteoh777
·2022-01-06
Maybe buy when the price is below 200. Market is rejecting moderna price at the moment.
Reply
Like
Report
一初心一
·2022-01-05
Please like, thanks
Reply
3
Report
Fold Replies
- 一初心一:
  done
  2022-01-05
  Reply
  Report
Tanyl
·2022-01-05
Can invest Moderna as well
Reply
2
Report
SandDust
·2022-01-05
Buy Put
Reply
1
Report
amybunny
·2022-01-05
Sit tight
Reply
Like
Report
btoh
·2022-01-05
K
Reply
1
Report
Yulio
·2022-01-05
Like
Reply
2
Report
KopiLim
·2022-01-05
Ok
Reply
3
Report
Kevin92
·2022-01-05
Like
Reply
3
Report
Kazmir
·2022-01-05
Like
Reply
4
Report
Joshua87
·2022-01-05
Like please
Reply
4
Report
Joastrid
·2022-01-05
Biotech stock
Reply
3
Report
ongcjeric
·2022-01-05
J
Reply
2
Report
JTBY
·2022-01-05
Yes, BUY
Reply
2
Report
edwinong
·2022-01-05
Like
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2201236325?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-05 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2201236325","market":"us","top_or_hot":-1,"title":"Is Now a Good Time to Buy Moderna Stock?","media":"Motley Fool","content":"<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","article_id":"2201236325","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","pubTimestamp":1641385443,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"现在是购买现代股票的好时机吗？","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"430047":1,"430090":1,"430198":1,"430418":1,"430489":1,"430510":1,"CDC":1,"MRNA":1},"content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9008807772,"gmtCreate":1641400325602,"gmtModify":1676533610870,"author":{"id":"4093015537749630","authorId":"4093015537749630","name":"lawteoh777","avatar":"https://static.tigerbbs.com/5ae1877cb7a2cdc2cf639fc280bc02e5","vip":1,"hat":"https://static.tigerbbs.com/3b7820dfed76481d8dc4de6ac5a7a136","crmLevel":1,"crmLevelSwitch":0,"idStr":"4093015537749630","authorIdStr":"4093015537749630"},"htmlText":"Maybe buy when the price is below 200. Market is rejecting moderna price at the moment.&nbsp;","listText":"Maybe buy when the price is below 200. Market is rejecting moderna price at the moment.&nbsp;","text":"Maybe buy when the price is below 200. Market is rejecting moderna price at the moment.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008807772","repostId":2201236325,"repostType":2,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":695804858,"gmtCreate":1641388587495,"gmtModify":1676532532756,"author":{"id":"3579259159683278","authorId":"3579259159683278","name":"一初心一","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3579259159683278","authorIdStr":"3579259159683278"},"htmlText":"Please like, thanks","listText":"Please like, thanks","text":"Please like, thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/695804858","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7156786,"gmtCreate":1641388603711,"gmtModify":1663239399840,"authorId":3579259159683278,"author":{"id":3579259159683278,"idStr":"3579259159683278","authorId":3579259159683278,"name":"一初心一","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":695804858,"type":1,"supId":0,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"}],"langContent":"CN"},{"id":9008183966,"gmtCreate":1641388459689,"gmtModify":1676533608959,"author":{"id":"4087109808120260","authorId":"4087109808120260","name":"Tanyl","avatar":"https://static.tigerbbs.com/174329973340cf0f5b68791ee5b08afd","vip":1,"crmLevel":9,"crmLevelSwitch":1,"idStr":"4087109808120260","authorIdStr":"4087109808120260"},"htmlText":"Can invest Moderna as well","listText":"Can invest Moderna as well","text":"Can invest Moderna as well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008183966","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008180628,"gmtCreate":1641388017048,"gmtModify":1676533608936,"author":{"id":"3581331938298103","authorId":"3581331938298103","name":"SandDust","avatar":"https://static.tigerbbs.com/ea6083d742fc232449a625fb122842c8","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3581331938298103","authorIdStr":"3581331938298103"},"htmlText":"Buy Put","listText":"Buy Put","text":"Buy Put","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008180628","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008180960,"gmtCreate":1641387952402,"gmtModify":1676533608920,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"htmlText":"Sit tight&nbsp;","listText":"Sit tight&nbsp;","text":"Sit tight","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008180960","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008112436,"gmtCreate":1641387326307,"gmtModify":1676533608669,"author":{"id":"3573789293829232","authorId":"3573789293829232","name":"btoh","avatar":"https://static.tigerbbs.com/5a7c2d714604fc804a48646ee397f912","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3573789293829232","authorIdStr":"3573789293829232"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008112436","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008113915,"gmtCreate":1641386201237,"gmtModify":1676533608551,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Yulio","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3583542338461065","authorIdStr":"3583542338461065"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008113915","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008119309,"gmtCreate":1641386091099,"gmtModify":1676533608529,"author":{"id":"3562886608344748","authorId":"3562886608344748","name":"KopiLim","avatar":"https://static.tigerbbs.com/04fcef53a2e715c173a40fafa14a7fe6","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":1,"idStr":"3562886608344748","authorIdStr":"3562886608344748"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008119309","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008110425,"gmtCreate":1641386062190,"gmtModify":1676533608521,"author":{"id":"3576274545052910","authorId":"3576274545052910","name":"Kevin92","avatar":"https://static.tigerbbs.com/c5ff4addbbdb8d9d15fec29f9709b0c3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576274545052910","authorIdStr":"3576274545052910"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008110425","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008110654,"gmtCreate":1641386013849,"gmtModify":1676533608513,"author":{"id":"3558609398993628","authorId":"3558609398993628","name":"Kazmir","avatar":"https://static.tigerbbs.com/6fbf34248b52f1c38a9dc30ae20b49d8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3558609398993628","authorIdStr":"3558609398993628"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008110654","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008110960,"gmtCreate":1641385819288,"gmtModify":1676533608521,"author":{"id":"3581682530927190","authorId":"3581682530927190","name":"Joshua87","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":3,"crmLevelSwitch":0,"idStr":"3581682530927190","authorIdStr":"3581682530927190"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008110960","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008110052,"gmtCreate":1641385787179,"gmtModify":1676533608505,"author":{"id":"3570936176869555","authorId":"3570936176869555","name":"Joastrid","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3570936176869555","authorIdStr":"3570936176869555"},"htmlText":"Biotech stock","listText":"Biotech stock","text":"Biotech stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008110052","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008137562,"gmtCreate":1641385737312,"gmtModify":1676533608513,"author":{"id":"3576895774513119","authorId":"3576895774513119","name":"ongcjeric","avatar":"https://static.tigerbbs.com/a4eece6de8f766cfa9770954976d8ae8","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3576895774513119","authorIdStr":"3576895774513119"},"htmlText":"J","listText":"J","text":"J","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008137562","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008137279,"gmtCreate":1641385696631,"gmtModify":1676533608498,"author":{"id":"4098795214586750","authorId":"4098795214586750","name":"JTBY","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/50a4c8d97279fa9f8f1fa9749a6bdff4","crmLevel":8,"crmLevelSwitch":0,"idStr":"4098795214586750","authorIdStr":"4098795214586750"},"htmlText":"Yes, BUY","listText":"Yes, BUY","text":"Yes, BUY","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008137279","repostId":2201236325,"repostType":2,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008137156,"gmtCreate":1641385653756,"gmtModify":1676533608490,"author":{"id":"3581723087274150","authorId":"3581723087274150","name":"edwinong","avatar":"https://static.tigerbbs.com/d42f3dae28f8c1740e66011b66f51ccd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581723087274150","authorIdStr":"3581723087274150"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008137156","repostId":2201236325,"repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":54,"commentSize":15,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}